Company registration number 07272699 (England and Wal￿>
Charlty wlstratlon numb•r 1137689 (England and Walèsl
Charlty reglstrntlon number SC049777 Iscotlandl
PANCREATIC CANCER ACTION
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

PANCREATIC CANCER ACTION
LEGAL AND ADMINISTRATIVE INFORMATION
Trustees
N Menezes
R Legg
C Carter
E Cowan
N Longworth
G Codacci Pisanelli
D Slater
G Lesro
T Matthews
Secretary
T Matthews
Chorlty numbgr IEngland ond Wal•81 1137689
Ch•rlty number IS¢otlondl
SC049777
Company numb•r
07272699
PrlncSpal addr•s•
Suite 3.10 Covauft
Fullarton Road
Cambu51ang
Glasgow
G32 8YL
R•gl8t¢r•d offl¢•
3 London Square
Cross Lanes
Guil(Iford
GU1 1UJ
Audltor
liotts LLP
3 London Square
Cross Lanes
Guildford
GU1 1UJ
Correspondence address
Suile 3.10 Covault
Fullarton Road
Cambu51ang
Glasgow
G32 8YL

PANCREATIC CANCER ACTION
CONTENTS
Page
Chief Executive's foreword
Trustees, report
2-10
Statement ol Trustees, responsibilflies
Independent auditorfs report
12- 15
Slalemenl ol financial 8ctiviti'e8
18
8alan¢e shegl
17
Statement of cash flows
18
Notes to the financial s(a(ements
19-32

PANCREATIC CANCER ACTION
CHIEF EXECUTIVE'S FOREWORD
FOR THE YEAR ENDED 31 DECEAIBER 2025
Chl•f Ex•cutlv•'s Fof•word
Although l joined Pancreatic Cancer Aclion after the period covered by this report, l am delighted to have the
opportunity to reflect on the charity's work and achievements over the past year. These achievements are testament
to the dedication of our staff. trustees and volunleers. and to the generosty and commitment of our supporters.
fundraisers and partners across the UK.
Pancreatic cancer remains one of the toughest cancers, wilh survival rates improving far too slowly. Too many
people are still diagnosed at a late stage, when treatment options are limrted. This makes our mission more
important and urgent than ever. Earty diagnosis can give people more Irealment opts"ons, more time wth those they
love and the best possible chance ol survival.
Throughout the year, PanC￿atIC Cancer Aclion continued to raise public awareness of the signs and symptoms.
provide trusted information and support to people affected by the disease. antj work wrth hearthcare professionals
and researchers to irnprove eaty diagnosis. None of this work would be possible without the people who share their
experiences, raise vital funds. Campaign alongside us and help us reach communrties across the country.
Since joining as Chief Executsve. I have been 5tru¢k by the passion. expertise and detemiination that exist
throughout our Community. I have also seen Ihtr s¢ale of Ihe thallen9e ahead. Meaningfvl progress will require us lo
remain focustrd, use tsur r¥$ources ¢arefulty and work collaboratively with people affected by pancr&ali¢ cgncer,
healthcare professionals, researchers, polscymakers and other organIsa￿onS that share our ambitions.
As we look to the future, we will build on Ihe strong loundations created by those who have supported and shaped
the charity. We will continue to put eaty diagnosis al the heart of everything we do and focus our efforts where we
believe Pancreatic CancerAction can make the greatest difference.
Thank you to everyone who has contributed to our work during the year. Your support, commitrnent and belief in our
mission make our work possible. I look forward to working alongside you as we tske ihe chanty into rts next chapter.
P.J. H_f..J
Paula Hanford
Chlel Executlve Offlc•r
18 Sep 2026
Dale.,

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT)
FOR THE YEAR ENDED 31 DECEAIBER 2025
The Trustees present their annual report and financial ststements for the year ended 31 December 2025.
The finanaal statements have been prepared in accordance with the accounbng poliaes set out in note 1 to the
financial statements and compty with Ihe charity's Articles of Associabon. the Cornpanie5 Act 2006. the Charities
and Trustee Inve5trnent Iswtlandl Aot 2005. the Chaiities Accoun15 Iscouandl Regulation5 2006 las arnendedl
and 'Accounting and Reporting by Charitses. Staternent of Recommended Practice applicable to charities
preparing their accounts in accordance with the Financial Repo￿"n9 Standaid applicable in the UK and Republic
of Ireland IFRS 1021 leffective l January 20191".
Oblectlves and actlvltles
Our purpose
Pancreatic Cancer Action works to save lives through promoting eaty diagnosis of pancreatic cancer. We do this
through promoting g￿ater awafeness of the symptoms ol the disease. the funding and development of medical
educational programmes. SUPPOrting patients through improved information about pancreat￿ cancer either on
our website or in print and by funding research.
Our vlslon
Our vislon 1$ that ev¢ryon$ survNo$ pan¢reati¢ Can￿r.
Our ml881on
Our mission is to improve survival rates of pancrealic cancer by ensuring more people a￿ diagnosed earfy and
that everyone has access to effeC￿ve treatments. supporf. information and care.
Obl¢¢tlv•s
The charty's oblectlves arè..
Awarenes8 - increase public awareness and knovAedge of pancreatic
ncer and its 5ymptom5 to achieve earty diagnosis
Campalgn and lobby the 9ovemment and key stakeholders for chon98 lo
advance the standard of heatt￿￿ for individuals affected by panC￿atIC
cancer
Traln and proviilè pIon￿ring odu¢alional resour¢¢$ for our m8ai¢al and
healthcare communities
Innovatlve research
we lund il. we support it - lo improve earfy
diagnosis and develop effective treatments lo improve pancreatic ¢an¢trr
outcomes
Offer Ihe proviS￿Tr ol praclical and enKJtM)nal support and inlormation to
all affected by pancreatic cancer
Now - we are the action chanty and action Is needed mre than ever
before1
The Trustees have paid due regard to guidan￿ issued by the Charity Commission in deriding what activities the
charity should undertake.
Tho Trusttès. aetiviti6s
The Trustees meet regularly to develop and support strategies to meet the chantable objectives. The Trustees
currenty have a range ol skills and experience Ihat range from medicavsaenlffjc. legal, corporate govemance,
finan￿ and PR, direct and indirec¢ lived experience ol pan￿atIC cancer.
Role of volunteers I PCA Action Ambassadof3
The Charity receive5 the very welcome as51Stance of volunteers. who help support a range of projects tts raisè
awareness of pancreats"c canor, provide support, miew literature and lundraise in their communrt*s.
The charity seeks volunteer assistance via the website, social media and by word of mouth.
Publi¢ benefit statement
The Trustees Gonfirm that Ihey have complied wilh the duty in Sedion 4 of the Charrbes Act 2011 to have due
regard to the Charity Commission's general guidance on public beneffi.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Aehl•v8ments and p8rformaneè
Below are the highlights of our activty and work in 2025 in pursuit of our ongoing mission to improve survival
rates of pancreatic cancer by ensuring more people are diagnosed eaty and have access to effective treatments,
support, inforrnation and rare.
q. Awareness - increase public aknvrenvJs ond kno*ledge of ￿ncreatI¢ ¢¥ncer and Its •ymptoms to
achlèv• •a￿Y dlagnosls
Pancreatic Cancer Action provides individuals. communrties and organisalions with resources to help raise and
improve syrnplom awareness of pancreatic cancer. Through posters. leaflets, booklets, online resources, and
community-based activities, we aim to equip people with Ihe kno¥￿edge they need to recognise potential
syrnptoms and seek medic81 advice prompty.
Raising symptom awarène$$ is ¢entral to our mission lo improv& earty diagnosis and save livtrs. By helping
people recognise thè signs and symplom$ of pancreats¢ ¢anc•r, we encourage anyonè wth concèrns to conla¢t
thèir GP as as possible.
Our accredited health infomialion resources are available in both digrtal and printed fomats. In our commitment
to making high-quality heatth infornialion accessible lo a wide range of communities our key pancreatic cancer
awareness materials are available in larger print. braille and have also been Iranslated lor the six languages of
Polish. Urdu, Punjabi. Bengali. Arabic and Guiarab. io assisl people who do not have English as their first
language.
Throughout 2025, we continued to raise awareness of Ihe signs and symptoms of p8n¢reali¢ cancer in a variety
of ways. Our dedicated staff and volunteers played an important role In engaging directly with communities,
inltialing conversations about symptom awareness and reinforong the importance of earfy diagnosis. Our
distinctive purple-branded Pancanvan. displaying key symptom infomiat*)n, also helped us reach the public by
being positioned in prominent. high-footfall and high-traffic locations.
The striking mural of The Smrths bassist Andy Rourke. located on Ihe side of The Wheatsheaf Pub in
Manchester's Northern Quarter. continued to raise both awareness 8nd lunds for pancreatic cancer. Originally
unveiled on Worfd Pancreatic Cancer Day in 2024 as a tribute lo Andy's lile and legacy. the mur81 has since
beeome part of a popular tourist mural trail and a poignant dèstination lor fans visrtin9 from around the worfd. We
are grateful to the team at The Wheatsheaf Pub for their contsnued support of our awareness Inrtiatsves, including
the use of Pancreatic CancerAclion beer mats displaying inforniation about the syrnptoms ol pancreatic cancer.
For Pancreatic Cancer Awareness Monlh IPCAMI in November. we launched our new %DeadlyKillerf carnpaign,
which showcased thal pancreatic cancer is the deadliesl cornmon cancer and that spotting the signs early could
save live5. We highlighted th81 it strikes fasl. hi(Jes behind ordinary symptoms. an(J too often goes unnoticed until
il's loo late. The Gampaign was hard-hrtting. highty visual and aiffled lo expose the truth. pancre8tic can￿r is 8
silent killèr that doesn't wait or discriminate. Recoynising thè symptoms tayty and acting fast ¢ould vdv¢ 3 Irf&.
When you know the signs, you have a chance to fight back against this deadly killer.
The C￿allon of our '#Dead￿Killerf campaign was made possible once again by the support we received from
FREE Partners. who gifted their time and experts.se to create the campaign as part of their Free Love Initiative.
We are incredibty grateful lo work wrth this award-winning creative agency to develop impathl eye-catching
campaigns that provoke a slrong emolional response.
To extend the campaign's ￿a¢h. we invesled in digital and Oul-of-Home IOOHI advertising, complemented by
0rg8nic media wverage across traditional and digital channels. This inrjuded news wverage and interview5 on
local radio and television. helping us take our symptom-awareness message to wider audiences 8ClOSS the UK.
Our speci81 thanks go to the survivor5 8nd bereaved famity wnembers who sh8fed theif experiences 85 part of the
campaign and support media engagement all year-round, helping spouight real families affected by pancreatic
cancer through the power of case studies in print an¢J online. Wilh an urgent need to improve public awa￿ness,
education and understanding of pancreatic cancer. together. we can encourage more people to recognise
potential syrnptoms and seek medical advi￿ prompty.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
In addth.on to our #Dead￿Killerf campaign some in¢￿dible activrties and events happened throughout November
that raised awareness and generalerj income.
We continued lo support collaborative awareness campaigns wlh Lights UK and the World Pancreatic
Cancer Coalition, joining a global community united in raising awareness ol pancreatic cancer. Throughout
November 2025, and particularty on World Pancreaty'c Cancer Day. supporters helped to illuminate buildings and
18ndtnarks in purple, shining a light on the disease and cxe8tsng Opportunities to share vit81 syrnptOTn information.
These initiatives bring communities together and demonstrale the collectNe detemination to Improve outctsrnes
and survival for people affected by pancfeatic cancer.
We also invested In new resources to strengthen our communty awareness activities, including new pop-up
banners, branded table covers. faster card donation laalrties and pancreas4haped display boards. Together with
the limited-edition purple Tunnock's Teacakes generousty provided lo the charity. these resources helped attract
attention and provided valuable opportunrties to start conversations Jbout pancreatic cancer during Pancreatic
CancerAwarenes5 Month.
With the continued support of Neh¥ork Rail. Pancreatic Cancer Action mainlained a presence 81 major railway
st8tions across the UK, including Leeds. London Wdterloo, Edinburgh Wdverfey and Glasgow Central. These
busy locatsons with high foomalls, ènablè our staff and volunteèrs to èngage with thousands of pèoplè, shar¥
Inlormatlon about the signs and symptoms of pancreatic cancer and raise vrtal funds.
Our annual 'Purple Takeover, of Glasgow Central Slalion was once again a highlight of Pancreatic Cancer
AWa￿nesS Month. Organised by one ol our dedicated supporters. the event brought together volunteers,
supporters and performers for a memorable day of awareness and lundraising. Entertainment included the
Glasgow Rock Choir and The KC Communty Choir. vtho generousty returned to support the event. wilh some
new additions in 2025. induding The Kirkinlilloch Pipe Band.
The performances drew the attention of comrnuters and visitors. ￿aling valuable opportunitie5 for our
volunteers and team members 10 engage vthh Ihe public. r8i$e awareness of the signs and symptoms of
pan¢re8li¢ ¢an¢er 8nd ¢oll¢¢t vital fund$ lo support our work. Many people also ¢ho$& to 1&8v& 8 purple heart in
memory or recognition of a loved one affected by pan￿at1¢ cancer.. a moving tradits'on that has become a
meaningful part ol the event over the years.
We are incredibly grateful to our dedicated staff, volunteers and supporters who give their time. energy and
enthusiasm throughout the year lo raise awareness and fvnds in communities across the UK. from busy
shopping cenlres and raihyay slalions to local rvgby dubs and community events. Our thanks go to every
mernber ol the public who stops to talk. leam more aboul pancrealic cancer or support our work. Every
¢onver8atlon 18 an opportunlty to In¢re¥￿ ¥ymptom owor¢nM$, •n¢ouro9• ￿rI1•r dlogno818 and,
uliim4iely, h•lp 1ov* liv¥¥.
2. Campaign and lobby government and key ¥takeholdern for ¢h#ny io odv•n¢¢ th# $tsndord of
heolth¢are for people affected by pancreati¢ ¢an¢pr
With pancreatic cancer Incidence increasing. urgènt action is n8eded to improvè awarèness, earfy diagnosis,
treatment, patient experience and survival. Pancreatsc Cancer Action continues to advocate on behaw of patients
and families, engaging with govemments, MSPS, MPS. councillors and other key stakeholders to ensu
pancreatic cancer remains firnity on the political and heamhcare agenda.
Throughout 2025, we continued (o work in partnership with Cancer52, One Cancer Volce, the Less Survlvable
Cancers Taskforce, the Scottlsh Cancer Coalltlon, the North Cancer Alllance Iscotlandl, Wales Cancer
Alliance and other organisations and coalitions working to improve cancer outcomes. By working collaborativety.
we strengthen our wlledive voice and help ensure that the experiences and needs of patients 8nd c8rers remain
at the heart of policy development and govemment deas10￿Making.
The first Less Survivable Cancers Awareness Week took place 13￿19th January 2025, building on previous
success of Less Survivable Cancer Awareness Day. Organised by The Less Survivable Cancer TaSkfQr￿ of
which we are a supports'ng member, the aim is lo raise awareness ol the need to improve outcomes of brain,
lung, pancreatic, liver. oesophageal and slomach cancers. These six Can￿rS are responsible for hall of all
common cancer deaths and up to a quarter of all rancer cases. Together. wth other ¢haritie5 in the taskforce. we
carnpaign for improvernents in awareness. diagnosis and research. to d05e the deadty cancel gap and save
lives. Events took place acro55 all 4 nats'ons of the UK and we were pioud to attend a ieception at Scottish
Parfiament.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Vve have engaged individually and Collective￿ wrth govemments and polwmakers throughout the year, providing
evidence, insight and the perspectives of people affecled by pancreats'c Can￿r.
During 2025. Pancreatic Cancer Aclion provided input to Ihe development of Ihe UK Govemment's National
CanTrr Plan. helping to ensure that the experiences and needs of people affected by pancreatic cancer were
represented.
We continued to be an active partner in campaigning for ¥nprovements in pancreatic cancer diagn051S. treatment
and care acros$ England and Wdles.
This included our ongoing involvement with the National Pancreatic Can¢erAvdft. Pancreatic Cancer Action had
advocated for an audrt ol pancreatsc cancef dia9nosis and treatment for many years, eontributing to 8 feasibility
study in 2022 an¢J the development of a scoping document in 2023 to help identify priorities for pancreatic cancer
care. Following publication by the National Cancer Audrt Collaborating cent￿ INATCANI of its State of the
Nation Report in September 2024, covering care received by people diagnosed with pancreatic cancer in
England and Wales, we continued during 2025 to advocate for the audrt's findings and recommendations to
translate into meaningful improvements in practi￿.
We believe the evidence generated through Ihe audrt provides an important opportunity to drive p05rtive change,
inform the development ol guidelines, improve early dete¢iion and diagnosis, addre5$ v8ri81ions in care and
Ultimate￿ improve the experiences and outome$ ol people affe¢t&d by pan¢reab"¢ ¢anc¥r.
In November, represen¢8lives from Panc￿811¢ Cancer Action and Pan¢reali¢ C8ncer UK joined Members of the
Scottish Padiament for a cross-paty photocall, demonstrating united support for people affected by pancreatic
cancer and their families.
We provided MSPS with briefings ahead of the annual Scottish Parfiament debate marking Pancreatic Cancer
Awareness Month. which took place on Worfd Pancreatic Cancer Day. 20 November 2025. During the debate,
MSPS rellected on the impacl of pancrealic cancer wthin Iheir communities. ￿Cognised the contribution of
patients. families, volunteers. lundraisers and charities. induding Pancreatic Cancer Action, and called on the
S¢ollish Government to accelerate adion and ￿mmitmentS io improvtr pan¢reab¢ ¢8n¢er out¢ome$.
We continued lo carnpaign for the leaming and improvements achieved through the SHPBN Pathway
Improvèmènt Projèct for pancrèatic and hèpatocellular cancer ISCOT-HPBI to ￿ embedded into fijture practic&,
lundlng and service development. As a key chanty partner in the SCOT-HPB project, Pancreatic Cancer Action
was proud to conlnbule to work that demonstrated improvements in the pathway from suspicion of cancer
through to diagnosis and treatment. The project also achieved positive advances in bmety and coordinated
communication. benefiting palienls, Ca￿r$ and healthcare prolessionals.
In Novernber 2025, Ihe results of the pathway improvement project We￿ published in The European Joumal of
Surgical Oncology IEJSOI. enabling the leaming and achievemenls of Ihe project to be shared beyond Scotland.
Peer reviewed by experts. the publication in the highty repulable medic81 joum81 was a 5ignific8nl athievemenl
lor all that were involved in the pioneerin9 Pathway ImpTovement project. This was also ￿ferenCed by MSPS
during the annual Scottish Parliamenl debate, helping to shine a spouight on Ihe progress achieved and the need
lor further action.
The annual Scottish Cancer Conference which took place in November 2025 at the University of Strathctyde's
Technology and Innovats'on Centre included discussions on the updated Scottish Cancer Referral Guidelines,
published in 2025, which incorporaled ￿commendatIOnS from Pancreatic Cancer Action.
While progress is being rnade. the pace of improvement musl accelerate. Pancreatic Cancer Action will continue
to pre53 for change and represent the voices and experiences of patients and carers, building on many years of
C8rnpaigning and collectNe 8Ction by our ci)fflmunrty-
We will continue to work a10￿gS1de patients. families, heaNh¢8re profr$sional$, poliwnakers and p8rtner
organisations tts inlluence meaningtul and lasting change.
Our focus remain5 dear". earty diagnos15. better patient experiences. improved acee#s to timely and
èffectlv• caro, and ultlmat•ly, morè Il¥t$ sav•d Irom pancrnatlc cancer.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
3. Traln and provldè plon••rlng •dueatSonal r•soure•s lor our m8dleal and healtheam communltl•s.
Pancreatic Cancer Action provides PKJneering accredrted e4eaming for healthcare professionals which
contribute3 to their Continuous Professional Developmenl ICPD} requirements.
Our GP e-18arning module is hosted by The Royal College of General Piactitsoneis IRCGPI.
Our Phamacy Team e4eaming module is hosted by The Royal Phamaceutical Society IRPSI, British
Oncological Phamiaceutical Assoaation IBOPAI, The NHS Leaming Hub and ELE Leam.
Throughout 2025, we continue¢J to Pfovide GP and phamiacy infomation packs across the UK. We are grateful
to our dedicated community of volunteers. who play an important role in distributing these resources and raising
awarenes5 Wlthin their local comrnunities.
In November 2025 we attended a GP Awareness Event in Dunstable. which provided a unique opportunity to
engage with GPS and local patients. Wh a presentation on raising awarene55 of pancreatic cancer. pancre8tic
health and diabetes management we were able to shine a li9hl on Ihe importsnce of awareness and education
and provide resources lo share wrth wider public and heamhcare professional netwoths.
We look lo￿ard to ¢ontinuing our woth wrth m&di¢al and hèalth¢arè prof&s$ional$ to improvo awar¥n¢$s and
&du¢ation. and ultimatety support the eadier tlw9no$6s of panue* ¢an¢er.
4. Innovatlv• r•8•areh w• fund It, w• •upport It to Improv• èarty dlagnosls and d•v•lop •ff8etlv•
tr•atm•nts to Improv• pancr•atle eanc•r outcom•8.
Pancreatic Cancer Action has a strong track fecord ol providing pump-priming seed funding lo kick-start
innovative research projects. helping promising ideas generate the evidence needed to attract larger-scale
investrnent frorn other funders.
A5 a small charity. we are not in a position to invest millions of pounds in research on ttte same scale as larger
organisations. Instead. we focus our resources where we believe Ihey can act as a catalyst for innovation and
further investment. We a￿ proud lo support tsrgeted ￿SearCh projects thal use dala and Science lo improve our
undsrstanding ol pancreat￿ cancel and explorè new opportunrtiès lor èarfier diagnosis and morè èffèctiv¥
treatment.
A powerful èxamplè of this approad) is our ongoing partnèrship wrth Dr Agnieszka Lemanska and the research
team at the Universrty of Surrey. Pancreabc Cancer Action provided initial funding lor research examining the
relationship tse￿een diabetes and pancreatic Can￿1. The retrospective case-control study analysed a large
sample of GP records from people with diabeles. comparing those who subsequentty developed pancreatic
cancer wth those who did not.
The findings helped build the evidence for a proactive case-finding approach focused on people with new-onsel
diabetes and unexplained weight loss. PanrJeatic Cancer Action cOn￿'nued to work wilh the Universty of Surrey
8nd NHS England as thè work developèd. In 2025, NHS Enyland launchèd a Ihrèe-year pilot, backed by almost
£2 million of targeted funding, through which more Ihan 300 GP practices In England would search patient
records to identify people aged over 60 wth new-onset diabetes and unexpected weight loss and refer those
considered al risk lor further investigation.
This represents an important step towards translaling research into dinical practice. The pilot seeks to
proactively identify people who may be at increased risk of pancreatic cancer and offer further investigation (o
confimi or rule out the disease. with Ihe potential lo support earty diagnosi5. For Pancreatic Cancer Action, this
demonstrates the significant impact that carefulty t8rgeteil seed lunding ran have. Our initial investment helped
innovats.ve ieseaich piogress to a much laiger4CAle progiammè, attracting substsnb.al addrtional funding and
¢￿atIng the potential to benefft many more pth"ents.
We are committed to supptsrting further innovath.ve research the potents.al to advance earty diagnosis and
improve outcomes for people affected by pan￿at1¢ cancer.
We continue to be proud members of The Assouation of Medical Research Chariiies IAMRCI and follow their
best practi￿ research gU￿elIneS.
Our contribution to research extends beyond providing funding. Pancrealic CancerAction also plays an important
role in supporting the wder ￿searCh communty by ensuring that the voices and lived experiences of patients
and carer5 are represented.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Through Patient and Public Involvement IPPl}, we support researchers and research projects to incorporate the
perspectives of people affected by pancrealic cancer throughout Ihe research process. Meaningful involvement
ol patients and carers helps ensure that research questions. prionties and approaches reflect what matters to
those with lived experience of the disease.
In May 2025 we provided support and attended The London P8ncre8s Workshop - a forum for state of the art
clinio81 8nd basic research in pancre81ic Con￿[. Organised by members of The Queen Mary University of
London, the workshop convenes every two years at The Barts Cancer Instrtute, tts discuss a wde lange of topics
relatin9 to the disease, attracting delegates from Ihe UK and abroad induding dinicians, saentists,
phamiaceutical companies and chanties. The 2025 programme induded topics ol diagnostic studies, dinical
trials, preclinical work to target pancreatic cancer and poster presenlalh)ns. We provided a range of our health
information and support resources and had very engaging chats wth the event attendees.
At the beginning of November, The UnNersty of Surrey research sludent that PCA supports hosted an event
'C8n We c8tGh it e8rliefi P8ncre8tlG G8nc&r awareness public perwectives- as part of the ESRC Festival of
Social Science. We were proud lo attend the event with one of our volunteers who shared her experience as a
pancreatic cancer survivor, providing an inspiring insight to why research is crucial to Improving survival.
were grateful to have the opportunty to talk to attendees aboul the work of Pancreatic Cancer Action, and with
the event aptly coinciding with Pancreatic Cancer Awareness Month share our Deadly Killer campaign and
provide quick guides to pancreatic cancer.
We will continue to champion innovative research. collaboration and meaningful patient invofvemenl. using our
resources and influence to help turn promising ideas into opportuni1￿6 for earlier diagnosis. better treatrnenl and
irnproved outcomes.
S. Offer tho provljlon of prnctlcal and emO￿on￿l iupport and Inlonnatlon to all affected by pancreatlc
¢•n¢•r.
People 8ffe¢ted by pan¢reali¢ cancer need information they can trusi. p8rti¢ularly when they are processing a
diagnosis, considering Irealmenl or supporting someone dose lo them. Panc￿4￿¢ Cancel Action provides clear,
practical Information covenng different stages of the panueatic cancer experience.
Our resources are reviewed by appropriat&ty qualffied medical professionals and independently assessad
through the pat￿nt Information Forum's PIF TICK accreditatsjn scheme. Patients, families, heatthcare
professionals and other expert reviewers also contribute lo their developmenl. helping us ensure that the
information is accurate, evidenc&based and accessible.
Our modular booklets allow people to choose the infomiation most relevant to their needs. Resources a
available digilalty through our websile. while printed copies can be ordered free of charge by individuals,
hospitsls. cancer support cenlres and other organisations.
Our specialist recipe book. Nouiishing Your Bcxly During P8nCle81￿ Cancer Trt8tmenl, ¢onlinues lo provide
practical nutritional guid8ncè and recipès dèvèlop￿1 for peoplè affècted ty pancrèatic cancèr.
Our guid8. rh8 Rol8 of G81J&tics in Pèncr88tAC Cancèr. explains inherited risk. 9enetic conditions associatèd with
pancreatic cancer, genetic testing and the support availablè lo people who may be eligible for testing. It also
highlights the signs and symptoms everyone should be awa￿ of.
Developing and reviewing accfedrted heatth infom)ation is a thornugh and collaborative process. It invofves
medical experts, peer and lay miewers, patients and families, heallhcare leaders and other charrties. This
ensures that our resources remain accurate. relevanl and genuinety useful to the people who rety on them.
Pancreatic Can￿r Action continued to fund a dedicated Pancreatic Can￿r Clinical Nurse Specialist within the
Wesl of Scotland Cancer Nety￿r￿. Based at Glasgow Royal Infirmary. Ihe nurse works alongside the wider
specialist tearn to provide information. guidance and reassurance to patients and farnilies across the legion.
Support is provided in clinics. on hospital wards. al appointrnents and by telephone. The nurse also contributes
to weekly multidisciplinary team Tneeting5. where heatthGqre ptofessionals review patient5, needs. di8gnose5 8nd
treatment options and agree coordinated plans foi their care.
Our funded nurse specialist worked with our team to develop a pilot project of Purple ca￿ Boxes and Chemo
Care Bags, to provide practical support and reassuran￿ to people undergoing t￿atment for pancreatic cancer.
These resources complemented our Irusted heatLh inf0m￿tIOn by helping people feel better prepared and
supported during an exceplionalty difficult time.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Our staff and volunte&rs also attend hospitsl awareness stands. creating opportunities to speak direcuy with
patients and carers, listen to their concems and connect them wth relevant inft)rmation and support.
Fundralslng
In 2025. income was generated through a wide range of fvndraising aclivibes. and we are continually grateful to
our amazing supporters and their inspiring energy. passmjn. detemiination and commrtment to raising funds and
awareness lor p8ncreab'c cancer.
Supporters participated in challenge events including The London Marathon, The Great North Run, The Great
Scottish Run, The Edinburgh Marathon and various ￿￿alks, providing a shining example of the amazing events
in aties across the UK.
People braved skydives, bungee jumps and person81 challenges running. walking, swimming and clirnbing, with
an inspiring delerminalion lo honour loved one$ 8nd help Pan¢reats¢ Can¢erAcb'on in our mission of Saving lives
through early diagnosis.
Schools. workplaces, hotels and communities took part in PJS for Pancan in April and during the Summer we
encouraged people to host a"Bake. Brew and BBQ" event alongside marking our chantys 15hl year.
Our long-term charity Partner Just Employment Law IJELI h05ted their bi-8nnual Summer B811 in June 2025,
which was allended by over 500 people al The R8di$son Blu Hotel in Glasgow. raising tsver £105.000. We are $0
grateful for thè lantastic $upport from the JEL team and Iheir ne1w0￿. which ¢J&mon$tr8t&$ the power of
corporate partnerships helping raise vrtal aWaren￿S and funds for pancreatic cancer.
Community fvndraising activities look place throughout the year and we thank everyone who comes together to
embrace the fun in fundraising and help change the pancreatic cancer slory.
A 3peci81 thanks to our loyal fundraisers who hosl annual even15 from golf days and coffee momings. lo bingo
nights and ¢olourful l¥a¢tor ¥un$ every year, ¢onlinualty embraong OPPOrtuniti&$ lo'Tum It Purple."
Our virtual challenge "60 miles in Novemberf took pla￿ as part of Pancreatic Cancer Awareness Month,
attracting people from across the UK to raise funds and awareness for pancreatjc Can￿r.
Pancreatic Cancer Action's first ever rnatch-lvnding donation appeal took place in the first week of Decernbèr
2025. as p8rt ol The Big Give Chri5trnas Appeal. Wth thank5 lo pled9er$ and The Hospi181 Saturday Fund who
provided match funding tts enable donations from geneious donois to be doubled, we $urpa$$ed our target and
raised a total of £21,510 in 7 days.
We thank our incredible donors who support Pancreaiic Cancer ActKJn throughoul the year and the kindness of
people bequeathing legacy gifts to our charTty.
Tru¥t¥ ond grants
We are very grateful to the funders that generousty pmide grants to support our initiatives. actsvitses and
projects. In 2025 these included gifts from The 8othwell Charrtable Trust and The Hospital Saturday Fund.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Flnanelal re¥l•w
The resutts for the year ar8 5ummaris8d in th8 Statement of Financial Aclivities on page 16.
The Trustees 8re pleased to report that the charity's incoming iesouices for 2025 aTnounted to 1635.33412024..
£633,973), 12023." £752,504), 12022. £488,089), 12021". £754.2171, 12020." £1,256,477), an exceptional year
which Induded a one-off transfer of £607,560 due to the merger ￿th Pancreab"c Cancer Scotland and £58,781
through the Coronavirus Job Retention Schemel12019'. £786.5051,12018.' £892.8511,12017'. £757,812).
The Trustees would like to thank al those volunteers, fijndraisers and donors- ￿j￿Orate, trusts and foundations,
as well as individual donors who have supported the charity over the past years and upon whom we are
dependent.
Total spending on ¢harrt8bl& 8¢tivrties was £422,563 12024." £492,318). 12023.. £465,441). 12022.. £450,195),
12021.. £513,8741,12020." £437,838112019". £609,931112018." £669,1871.12017.. £669,077).
The charity achieve¢J a net deficit for the year of -£131,054 12024." -£222,4181, 12023." _£8,0771, 12022.. £-
241,7411.12021. £-87.7401,12020. £510.025112019. £-115,305112018. £-24,634112017. £-169,3151.
R•s•Tho8 pollcy
It is the policy of the charity that unrestricled funds which ha￿ not been designated for 8 5perific use should be
maintained lo cover 81 le8s16 months ol operating expendl1u￿. The Trustees consider that reserves 81 thi$ level
will Ènsure th81, in the èvenl ol a significant drop in funding, they will be abl& to continue the ¢harty'$ ¢urr¥nl
8¢tivitiès while consideration is gNen lo ways In whi¢h addiknonal funds may be raised.
At 31st December 2025. the charity held reserves 01 £238.907 01 which £47.972 was restricted. Free reserves
stood at £98,337, which is below our targel level. This reflected a combination of strategic investment in
organisational assets to strengthen ouf long-tem) capacty and the impact ol a ChaI￿nging operaling environment
lor charitie5 in the recent period.
To ensure tsur cost base rern8ins aligned with projecte(J income, trustees planned a review of our operating
model. including a restructuring lo reduce ongoing operaliny ¢o$l ¢ommitmenl$, which h8$ $in¢e btren
completed. These changes have created a mre e￿ient and sustainable organisalion while protectin9 the
qualrty of our services.
We expect our reserves to strengthen over time as these effiaenues are realised and our income continues to
diversify and grow. Rebuilding reserves remains a priority for the Board as part of our commrtment (o maintaining
the organisation's long-lerm financial resilience.
Structure. governance ond rnwno9ement
The charity is a company limited by guaranlee. incorporated in June 2010, and is therefore govemed by rts
Articles of Assoriation. Ils company registration number is 07272699 and lis charity numbers are 1137689
IEngland and Wales) and SC049777 (Scotlandl.
Thè Trustees, who are also the directors lor thè purposè of company18w, and who seNèd during thè y8ar and up
to the date of signature of the financial statements were..
N Menezès
R Legg
C Carter
E Cowan
N Longworth
L Nylandei
G Codaca Pisanelli
D Slater
G Lesca
T Matthews
IRe$i9ned 28 Odijber 20251
None of the Trustees has any beneficial interesl in the charity. The members of the o)mpany guarantee to
contribute £10 in the event of liquidation.

PANCREATIC CANCER ACTION
TRUSTEES, REPORT (INCLUDING DIRECTORS, REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
The Trustees continu8 to keep the Chariws activities under r8view. patticularty wth iegaid to any major physical
or financial risks that rnay arise from tsrne to time, and tts monrtor Ihe effectiveness of the systetll of internal
controls and other variable means. including insurance cover where appropriate, by which those risks already
identified by the Trustees can be mrtigated.
Auditor
In accordance with the companys articles, a resolution proposing that Mliotts LLP be reappointed as auditor of
the company will be put at The Annual General Meeting and be subject to the requirements of audit.
Dljrl￿Ur9 of Inforrnatlon to audltor
Each ol the Trustees has confirnied that there is no inf0m￿tion ol which Ihey are aware which is relevant to the
audit, but of which the auditor is unaware. They have fvrther Confinned thal they have taken appropriate steps to
identify such relevant informatson and to eslablish thal the audrtor is aw8re of such information.
The Trustees, report was approved by the Board of Tnjstees.
,J,. ca_, p,-.11,
G Codacel Pl$an•lll
Chair ol Trustees 18 Sep 2026
Dated..
10-

PANCREATIC CANCER ACTION
STATEMENT OF TRUSTEES, RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEAIBER 2025
The Trustees, who are also the directors of Panueab"c Cancer Action for the purpose of company law, are
responsible lor preparing the Trustees, Report and the financtal stalements in accordance with applicable law and
United Kingdom Accounting Standards Iunited Kingdom GeneraltyAccepted Accounting Practice).
Company law requires the Trustees to prepare ffinanryal $tslements for eadh fin8ncial year which gNe 8 true and fair
view of the state ol aYfair5 01 the chanty and of the incoming resources and applicAtion of resouices, induding th8
income and expendrture, ol the charrtable company that yeaf.
In preparing these financial statements, the Trustees are requifed to..
select suitable accounting policies and Ihen appty Ihem consislentty.,
observe the methods and principles in the Charrlies SORP..
Make judgernenls and esb'm8tes that are reasonable and pwdenl..
state whether applicable UK Accounting Standards have been followed, $ubie¢t to any material dèpartures
disclosed and explained in the financial statements", and
prepare the financial stalemenls on the going concem basis unless it 1$ inappropriate to presume that the ¢harfty
11 continue in operatson.
The Trustees are responsible lor keeping adequale accounbng records th8t disdose wilh reasonable accuracy at
any time the financial position of the charity and enable them to ensure that Ihe financial stalements comply wrth the
Companies Act 2006. the Charilies and Trustee Inve$iment (Scotlandl Act 2005 and the Charities Accounts
IS¢ollandl Regulations 2006. Thw are also re$pon$ibl& for $afeguardin9 th* ass*ts of th¥ ¢hgrrty and hence ftsr
taking reasonable steps fof the Pfevenlion and delection of fraud and other irregularities.

PANCREATIC CANCER ACTION
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION
Oplnlon
We havè audited financial ststements of Panueatic CanrAr Acbon Ithe 'charty'l for thè year ended 31
Decembei 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows
and notes to the finanaal statements, induding signthcant accounb.ng poliaes. The financial reporting framework
that has been applied in their p￿paratIOn is applicable law and Uniled Kingdom Accounting Standards, including
Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland
Iunited Kingdom Generalty Accepted Accountsng Pracb'rEI.
In our opinion, the financial staternents..
give a tnje and lair view of the stale of the charitable companrfs affairs as at 31 December 2025 and of its
incoming resources and application of resourcEs. induding its income and expenditure. for the year then
ended..
have been properfy prepared in accordance wrth United Kingdom Generalty Accepted Accounting Practice,.
and
have been p￿pa￿l in accordan¢& vrith lh& reqU1￿MentS of tho Ccthpani&$ Ad 20rA, Ihe Charili&s and
Trustee Investment (Scotlandl Act 2C*)5 and ￿gulatt"0n 8 of the chartti.es Accounts Iscotlandl Regulatlons
2006.
Basls for oplnlon
We conducted our audit in accordancè with Intèmational Slandards on Auditing ILIKI IISAS IUKII and appllcable
law. Our responsibilities under those slan¢Jards are further described in Ihe Audilorfs ￿sponsIbl1111eS for the audit of
the fin8nci&l stetemenls section of our report. We are independent of the charity in accordance wrth the ethical
requirements that are relevant to our audit of the ffinancial statements in the UK, including the FRC'S Ethical
Standard, and we have ￿￿illed OUT olher elhical responsibililbes in 8ccordance with these requirements. We believe
that the audit &viden¢e we have oblained is suffi¢ieni and appropriate to pro¥id& a basis ltsr our opiniorn.
Coneluslon8 r•latlng to golng eonc•m
We draw attention to Note 1.2 to the finanual slatemenls. which sets out the Truslees, assessment of Ihe Charity's
ability lo continue as a goin9 concern and Ihe basi3 on vthith the financial slalements have been prePa￿d.
Th¥ Trust6eS' 8ssèssment acknowledges that the Charity is èxpèriencing cash llow pr&$$ures and is reliant on an
improvement in financial performance and the generation of a¢Jditional income lo maintain suffiaent cash resources
to meet its liabilrties as they fall due. The Trustees and management are aware of these pressures and have taken,
and continue to take, appropriate action to manage the Charity's finanaal position.
As Part of our audit. we have reviewed management'5 going concem assessment. induding the budgets. ¢88h Ilow
forècasts and assumptions underlying the lorecasts. We have consKJerèd the actions being taken by managemènt
to address the Chanty's cash flow position, induding the review of budgets and expenditure, cost-saving measures
and the restructuring ol staffing arrangements. We have also considered the Charty's plans for future income
generation, including antiupated legacies, grant applications and other fundraising activities.
Based on Ihe work performed. we con5Kler management's assessment of going concem and the assumptions
underlying the forec8sls lo be reasonable. We have 8150 considered the adequacy of the disd05ure5 made in Note
1.2 in respect ofthe Ch8nty's going concem assessment.
Based on the audrt ewdence obtained, we have nol identffied any material uncertainty relating to events or
conditions that, individualty or collectivety. may cast signthcant doubt on the Chanty's ability (o continue as a going
concern. Accordingly. our opinion is not modified in respect of this matter.
12_

PANCREATIC CANCER ACTION
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION
Othar Infomiatoon
The other information comprises the informalion included in the annual report other than the financial statements
and our auditorfs report thereon. The Trustee5 are iesponsible for the othef Infofrnation contained within the annual
report. Our opinion on the financial statements does not cover the other infomation and, except to the extent
otherwise explicitly stated in our report, we do not express any forni of assurance conclusion thereon. Our
responsibility is lo read the other inforniabon and. in doing so. consider whether the other infomiation is materially
inconsistent with the financial ststements or our kn￿￿edge obtained in the course ol the audrt. or otherwise appears
to be materially misstated. If we identfy suth material inconsislencie5 or apparent rnaterial mis5tatement5. we are
required to determine whether this gives rise lo a fflaterial misstatement in the financial ststements themselves. If.
based on the work we have perfomed, we conclude thal there is a matenal misstatement ol this other infomation,
we are required to report that fact.
We have nothing to report in this regard.
Oplnlono on other matters prescrlbed by the Companles Act 2006
In our opinion, based on the work undertaken in the course ol our audit..
the information given in the Trustees. report for the finanri81 year for whKh the financial $18lemenls ar
prepared, which includès thè diréctors, rèport pr&parèd for thè pufpos¢s of company law, 1$ ¢on$istènt wfth th&
financial statements," and
the directors, report included vrithin Ihe Trustees. report has been prepared in accordance with applicable legal
requirements.
Mattors on whlch w• aré r•qulr•d to f•port by •xeèptlon
In the light of the kn￿edge and underslanding ol the ch8rity and ils environment obtained in the course of the
audit, we have not identified material misstalements in Ihe directors, report included wrthin the Trustees, report.
We hav8 nothing to rèport in respect of th8 following matters in rèlation to whKh the Compani¢$ Act 2006 and the
Charities Accounts (Scotlandl Regulations 2006 require us to report to you rf. in our opinh)n.
adequate and proper accounting record5 have not been kepl. or retums adequate for our audit have not been
received Irom br8n¢hes not visited by us,. or
the financial slalements are not in agreement wrth Ihe accounbng records and retums,. or
c6rt8in disclosurès of trustèès, remuneration speufied by law arè not madè". or
we have not receNed all Ihe information and explanations we require for our audit.. or
the Trustees We￿ not entilJe¢J to prepare the finanoal stalemenls in accordance wth the small companies
regime and take advantage ol the small companies. exemptions in preparing the Trustees, report and from the
requirement to p￿pa￿ a strategic report.
Responslbllltles of Trustees
As explained more ful￿ in the statement of Trustees, responsibilrties. the Trustees. who are also the directors ol the
charity for the purpose of company law. a￿ responsible for the prepara(H)n of Ihe financial statements and for being
satisfied that they give a Irue and fair view. and for such intemal control as the Trustees deterrnine is necessary to
enable the preparation of financial statements that are free from material rnisstaternent. whether due lo fraud or
error. In preparing the financial statements, the Trustees are responsible for assessing the charty's ability to
continue as a going concern, disdosing. as applicablÈ, rnattets related to going concem and using the going
concern basis of accounting unless the Trustees erther intend to liquHYate the charitable company or to cease
operations, or have no realistsc altematNe Lwjt to do so.
13-

PANCREATIC CANCER ACTION
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION
Audltorfs r&sponslbllbtl•s forth• audlt of the financlal ststemènts
We have be8n appointed as auditor under section 4411 Ilcl of the Cha[1t￿S and Trustee Investment Iscouandl Act
2005 and under the Cofflpanies Act 20(￿ and report in a¢xordance wrth the Acts and ielevant regulations made 01
having effect thereunder.
Our objectives are to obtain reasonable assurance aboul whether the finanaal slatements as a whole are free from
material misslaternenl. whether due lo fraud or error. and lo issue an audilorfs report that includes our opinion.
Reasonable assurance is a high level ol assurance but is not a guarantee that an audit conducted in accordance
with ISAS IUKI will 8fv4ays detect a material misstatement when it exists. Misstatements can 8rise trorn fi8ud or
error and are ¢onsidered material il, individualty or in the a99reg*e. they could ieasonabty be expected to influonc
the economlc decisions of users taken on the basis of Ihese finanual statements.
Irregularities. including fraud, are instances of non-compliance wilh laws and regulations. We design procedures in
line with our responsibilrties, oullined above. to detect material misstatements in respect of irregularities. induding
fraud. The extent to which our procedure5 a￿ capable of detecting irregularities. including fraud, is detsiled below.
Extent to whlch the 4udlt wo¥ con?IdeTrd c?pablg of detectlng Irregul¥rlt1￿, Includlng fraud
Our approach to identifying and assessing the nsks ol matenal misstatement In respect of irregularilles. Induding
fraud and non-compliance with laws and regulations. was as follows".
the engagement partner ensured Ihal the engagement team collectivety had the appropriate competence,
capabilities and skills to identify or recognise nonllc0mp1ian￿ with applicable laws and regulations..
we identified the laws and regulalions applicable to the company through discussions wrth Trustees and
other rn8n89emenl. and from our knowledge and experience ol the sector..
we focused on $petyfi¢ 18ws and regulations which we ¢onsidered may havo a direct material efttr¢t on Ihtr
financial statements or the operations ol the chantable company. including the Companies Act 2006, the
Charrties Act 2011, the Charities SORP. taxal￿n legislabon. data protection, anti-bnbery, employment,
environrnenlal and heahh and safety legislation..
we assessed the extenl of compliance with Ihe laws and regulabons idents'fied above through making
enquiries of rnanagernenl and inspecting leg81 correspondence.. and
identrfied laws and regulations were ¢ommuni¢aied within the audrt leam regularty and the team remained
alert to instances ol non-compliance throughout the audrt.
We assessed the suscepltbSltty ol the charitable company's finanaal statements to material misstatèment. Including
obtaining an understanding of how fraud might occur. by..
making enquiries of rnanagemenl as to where they conSide￿d the￿ was susceptibility to fraud, their
knowledge of actual. suspected and alleged fraud.. and
considering the internal controls in place lo mitigale risks of fraud and non-compliance with laws and
regulations.
Audlt rnspon8• to rfsks Id•ntlfi•d
To a¢Jdress the nsk offraud through management bias and override of controls, we."
performed analytical procedures lo identfy any unusual or unexpected relationships,.
reviewed all transactions listed..
a55es5ed whether judgemen15 and assumptions made in determining Ihe accounting e5timale5 were
indicative of F)Otenlial bias", and
investigated the r8ts"onalè behind signifi¢Ant or unusual transactK)ns.
In response to the risk of irregulanlies and non-complian￿ vthh laws and regulab"ons. we designed procedures
which included, bul were not limited to..
agreeing financial staternent disdosures to undertying sUppO￿.ng dowmentstion.. and
enquiring of management as to actu81 and potenbal liligalion and daims.
14_

PANCREATIC CANCER ACTION
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION
There are inherent Iimrtabons in our audit prO￿dureS described above. The more removed that laws and
regulations are from finanaal transactions. the less like￿ il is Ihal we would become aware of non-compliance.
Auditing standards also limit the audit prC￿dU1eS required to identify non-compliance with laws and regulations to
enquiry of the Trustees and other management and the inspeclion of regulatory and legal correspondence, rf 8ny.
M8t81i&l mi5Statements that arise due to fraud (*n bè hArdèr to dètèct than thtssè that aiise from orror as thèy MAY
involve deliberate concealment or collusion.
A further description of our responsibilities is available on the Finanaal Reporting Council's website at.. https'.11
w¥vw.frc.org.uklauditorsresponsibilities. This description forms part of our auditorfs report.
U89 of our rgport
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 01 Part 16
of the Companies Act 2006. and lo the charilable company's trustees, as a body. in accordance with Regulation 10
of the Charities Accounts Iscouandl Regulabons 21￿. Our audrt work has been undertaken 50 that we might state
lo the charrtable cornpany s members and iruslee5 those matter5 we are required to state to them in an auditor's
report and for no other purpose. To thè lullesl extent pemirtled by law, we do not a¢¢ept or assume responsibility to
anyone other than thè charrtable company, thè chanlable company's members as a body and the charitablè
company's trustees as a body, for our audit work. for this report, or for the opinions we have lomied.
St•phen Meredlth BA FCA DChA IS•nlor Statutory Audltorl
for ond orb behall of Alllotts LLP
21 Sep 2028
Chart•r•d Accountants
ststulory Audltor
3 London Squartr
Cross Lanes
Guildlord
GU1 1UJ
15-

PANCREATIC CANCER ACTION
STATEMENT OF FINANCIAL ACTIVITIES
(INCLUDING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2025
Unrestrlcted Restrlcted
lunds
funds
2025
2025
Total Unrestrlcted Restrlcted
funds
funds
2024
2024
Total
202S
2024
Notes
Incom• frt>m=
Donations and legacies
Other trading activities
Investments
19.607
629.267
2.354
3.713
594.096
2.943
7.670
29.264
623.360
2,943
7.670
2,354
3.713
Totsl Incorn?
615,727
19,607
635,334
604.709
29.264
633,973
Expendlture on..
Raising funds
Charltablè activlti8$
339.749
351,564
4.078
70.999
343.825
422.563
322.757
317.928
41.316
174,390
364,073
492,318
Totsl •xp•ndltuM
891,313
75.07S
786.388
640.68S
21S.706
856,391
N•t •xp•ndltuM
175,586)
ISS,4681 1131.0541
13S.9781 1186.4421 1222,4181
Transfers behyeen
funds
{6.0931
6.093
N•1 mov•meni In
funds
175,586}
155,488) 1131.0541
142,0891 1180,3491 1222,4181
R•conelllatlon of lundg:
Fund ba18nces 811 January
2025
266,521
103,440
369.961
30B,S90
283,789
S92,379
Fund balanc•8 at 31
December 2025
190,935
47,972
238.9)7
2e6.S21
103.440
369,961
The statement of financial aclivth&s indudes all 9ains and kjsses reco9nised in the year. All income and expendrtur6
derive from continuing activities.
16-

PANCREATIC CANCER ACTION
BALANCE SHEET
AS AT 31 DECEMBER 2025
2025
2024
Notes
Flxed assets
Intangible assets
Tangible assets
12
13
74.503
18.095
46,012
27.253
92.598
73,265
Current a8set8
Stocks
Debtors
Cash al bank and in hana
14
15
9.378
84.869
109.110
4.565
54.375
331.620
203.357
390.560
Credltors.. arnounts folllng due vAthln
on• yoor
16
157,0481
193,8641
Nèt eurmnt a88èts
146,309
296,696
Totsl a8S•t8 1•88 eurr•nt Ilabllltl•8
238,907
369,961
Th• fund$ of th• ¢horlty
Restricted incorne funds
Unrestricted lund$
18
47.972
190,935
103,440
266,521
238,907
369,961
18 Sep 2026
The flnanclal statem8ntS W8r• approvèd by the Trust8e$ on .........................
&,J,- ￿.-. p. 11,
IIIB
G Codaccj Pisanelli
Chalr ol Tru•tO•8
17_

PANCREATIC CANCER ACTION
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEAIBER 2025
2025
2024
Note$
Cash flows from opèrating aetlvltl•s
Cash absorbed by operatsons
22
(191.223}
1142.0261
Inv•stlng actlvltl•s
Purchase of intangible assets
Purchase of tangible fixed assets
Investrnent income received
135.000)
147.1401
132,6001
7.670
3.713
Net cash used In In¥￿tIng acWvllle•
131.287)
172,0701
N•t ¢o¥h gon¢ratod from flnan¢lng •¢llvlW¢s
Nèt d•er•asè In eash and eash •quIva￿nts
1222.5101
1214,0981
Cash and cash equivalents at beginning of year
331.620
S45,716
Cash and ca8h equlvalents at •nd of year
109.110
331,620
18-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEAIBER 2025
Aecountlng pollel•s
Charfty Snforniatlon
Pancreatic Cancer Action is a registered tharrty and a company Incorporated by guarantee with no share
capital, exempted under section 5 of the Companies Act 2006 from the requirement to use 'Limrted" as part of
its name. It is incorporated in England and Wales undef registration number 07272699 and its registered
office is 3 London Square. Cross Lanes. Guildlord. England. GU1 1UJ. Correspondence address is Suite 3.10
Covautt. Fullarton Road. Cambuslang. Glasgow. G32 8YL.
1.1 Ba$1# of preparatlon
The financial statements have been prePa￿d in accordance wlh the charitys Statement ol Recommended
Practi￿ applicable to charities preparing accounts with the Financial Reporting Standard applicable in the UK
and Republic of Ireland IFRS 1021. the Companies Act 2006. the Charities and Trustee Investment IScoll8ndl
Act 2005, tre Ch8rilie$ Acwunts IScoU8ndl Regulations 2006 18$ arnendedl, FRS 102 'The Finanryal
Reporting Standard applicable in the UK and Republic of Ireland. I"FRS 102.1 and the Charrties SORP
"Accounting and Reporting by Charities." Statement ol Recommended Practice applicable to charities
preparing their accounts in accordance wth the Financial Repo￿n9 Standard applicable in the UK and
Republic ol Ireland IFRS 1021" (effective 1 January 20191. The charity is a Public Benefit Entity as defined by
FRS 102.
Th& finan¢i81 siatemenis 8r& prepared in Slerting, which is the ftJn¢b'onal curnency of th¥ ¢harity. Mon&tsry
amounts in thèse financial statement$ ar& rounded lo th¢ n&ar¢$l £.
The financial statements have been prepared under the historical cost CA)nvenbon. The principal accounting
policies adopted are set out below.
1.2 Golng concern
The Trustees have assessed Ihè Charrty's ability lo continue as a 9olng ¢on¢em for a pèrfod ol at least twelvè
months from the date of approval of these financial slalements.
In making this assessment, the Trustees considered the Charity's current ffinanaal position, cash flow
lorecasls and the prinupal risks and Un￿rtaIntieS lacing Ihe organisation. The Trustees recognise that the
external environment lor charitse8 remains chaMen9ing. wrth wnbnuing pre6sure6 on income generation.
funding and operating costs.
During the year, the Chanty has un(Jertaken a programme of significant COSt-saving measures. including a
restructuring of siaff, to Ènsure th81 expenditure 15 81ignÈd wilh antitypated levels of in¢ome and to Stienglhen
the Charty's long-term financial sustainabilrty. Cash flow lorecasts are preparèd lor règular ièvièw by thè
Trustees to ensure reasonable cOns￿eration of possible downside scenarios.
Having ￿VIeWed the Charity's financial forecasts, cash flow projections and available reserves, together wrth
the actions available to managemenl lo respond to changes in income or expenditure, the Trustees are
satisfied that the Charity has adequate resources lo continue rts operations for a period of at least ￿e1ve
months from the dale of approval of these financial slalemenls. The Trustees the￿fOre have a reasonable
eKpectation that the Charity ￿11 conty'nue as 8 going fg)nr*m and have adopted the going ¢on¢em basis in
preparing these financial Statements.
1.3 Charitable funds
Unrestricted funds are available for use al the discreb.on of the Trustees in furtherance of their chantable
objectsves.
Restricted lunds are subject to specthc cOndrt￿ns by donors or gtantors as to how they may be used. The
purposes and uses ofthe restricled lunds are set out in the notes to the finanaal statements.
1.4 Incom•
Income is recognised when the charity is legalty enlitled to it after any perfomiance conditions have been rnet.
the arnount5 can be rneasured reliabty. and rt 15 probable th8t inwme will be received.
19-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Accounting policies
(Continuedl
Cash donations are recogniseil on receipt. Other donath.ons are re(x>gnised once the charty has been notified
of the donation, unless perfomiance condib.ons require deferral ol the amount. Income tax recoverable in
relation to donations rece￿ed under or deeds ol covenant is recognised at the time of the donation.
Legacies are recognised on receipt or olhemse il the charity has been notified of an impendin9 distribution,
the amount is known, and receipt is expected. If the amount is not known, the legacy Is treated as a
contingent asset.
Glfts ol assets and sgrvi¢es a￿ r¥¢ognised at market Value to ¢harity.
1.5 Exp•ndltur*
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a
third paty. il is probable that a Iransfer of e￿nOMiC benefits will be require(l in settlement, and the arnounl of
the obligation can bo measured reliabty.
Expenditure is dassified by actwity. The costs of each activity are made up of the total of direct costs and
shared costs. including support costs involved in undertaking each acbvity. Direct costs attributable to a single
activity are allocated directy to that activity. Shared costs which conlribule to more than one activity and
support costs which are not attributsble to a single aclivity are apportioned befv4een those activities on a basis
consistent wrth the use of resources. Cenlral staff costs are allocated on the basis ol lime spent. and
deprwotlon ¢h8rge$ ¥r¢ •llo¢ai¢d on th* ports.on tsl lh¢ ass¢i'$ ustr.
Expenditu￿ has been allocated betsyeen the main headings in the Statement of Financial ActNth'es on the
basis of the type ol activity to which they relate. induding irrecoverable V.AT.
Income and expenses have not been netted off.
1.6 Intanglbl• Ilx•d assèts oth•r than goodwlll
Intangible assets acquired 5eparalety Irom a business are recognise(181 cost and are subsequently measured
81 cost le$$ accumulated amtsrtisalion and ac¢umul*èd impaimènt lo$￿$.
Intangible assets acquired on inlemalty generated assets are recognised at the acquisition date where it is
probable that the expected fu1U￿ economic beneffts Ihal are attributable lo the asset will flow to the entity and
the fair value ol the asset can be measured reliabty.. the intangible asset arises trom contractual or other legal
righls.. and the intangible asset is separable from the entity.
Amorh'sation is recognised so as lo write off the cost or valualion of assets less their residual values over their
useful INes on the follrring bases..
Sofvlare
Websf¢e De¥elopmenl Cost
33.3% on cost
14.3% on ry)s1
1.7 Tangible fixed assets
Tangible fixed assets are initialty measured at cost and subsequenty measured at cost or valuation, net of
depreciation and any impairmenl losses.
Depreuab"on is recognised so as to vnite off the cost or valuation of assets less their residual values over their
useful lives on the following bases".
Flxtures, ffith.ngs & equipment
Computers
Motor vehides
25%-33.3% on cost
25% on cost
25% on cost
-20-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Accounting policies
(Continuedl
The gain or loss arising on the disposal of an asset is detemiined as the dtherence between the sale proceeds
and the carrying value of the asset. and is recognised in the statement of finanual ath"wties.
1.8 Impainngnt of fixgd as¥et¥
At each reporting end date. the charity reviews the carying amounts ol its tangible and intangible assets to
determine whether there is any indicalion that those assets have suffered an impairrnent loss. If any such
indication exists. the recoverable amount of the assel is estirnated in order to determine the exient of the
imp8irtnent loss lif any).
1.9 Stocks
Stocks are stated at the lower ol cost and estimated selling price less costs to complete and sell. Cost
comprises direct materials and, where applicable. direct labour costs and those overheads that have been
incurred in bringing the stocks lo Iheir presenl Ic￿￿On and condition. Items held for dislribulion at no or
nominal consideration are measured the lower ol replacemenl cos¢ and cost.
Th¥ ¢harity 1$ r8cogni$in9 80% ol the $t¢xk a$ $lo¢k i$su&$ lo support a¢livilles ralsln9 fund$ and
awaren&$$. The balance recognisetl on Ihè balan￿ shèet 1$ the r¢$idual value of the stock.
Nel realisable value is the trstim8led selling pri¢& less 811 esiimaled ¢o$ls of completion and co81$ lo be
in¢urre¢J in markeling, Selling ana dislribulion.
1.10 Cash and ea8h oqulval•nts
Cash and cash equivalents include ¢a$h in h8nd. deposrts hekl at ¢811 with banks. othtrr $hort-lerm liguid
inveslrnenls with original maturities ol Ihre& monlhs or less, and bank overdr8ft$. Bank overdrafts are Shown
wbthin borrowings in curnent 11a￿lrt￿S.
1.11 Flnanclal In8trum•nts
The charity has elected lo appty the provision$ of Sedion 11 '88$i¢ Fin8nu81 In$trumtrnls' and Section 12
'Other Flnandal Instwments Issues, of FRS 102 to all of rts finanaal instruments.
Flnancial instrurnents are recognised in the chanty's balance sheet when the chanty becomes party to the
contradual provisions of the instrument.
Financial assets 8nd liabilitie5 are offset. wilh Ihe net amounts presenled in the financial statements, when
there 1$ 8 legalty enforceable right lo Sel off the re¢ognised amunts and there is an intention lo settle on 8 net
basis or to realisè th6 assèt 8nd sètuè thè liability simuM8neousty.
Baslc flnanclal ass•ts
Basic financial assets. which indude debtors and Gash and bank balances, 8re initially me8sured at
transaction price including transaction costs and are subsequenuy ¢Arried at amortised cost using the effective
interest method unless the arrangement constrtules a finanang transaction. where the transaction is
measured at the present value of Ihe luture receipts discounled at a market rate of interest. Finanaal assets
classified as r￿1Vable wrthin one year are not amortised.
21

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Accounting policies
(Continuedl
Basle finanelal Ilabilltiès
Basic finanrial liabilities. induding credrtors and bank loans are inrtially recognised at transaction price unless
the arrangement constrtutes a financing transaction. where the debt instwment is measured at the present
V81ue of the future payment5 discounted at a market rate of inlere51. Fin8nryal li8bilities classified 85 Payable
wrthin one year are not amortised.
Debt instruments are subsequentty carried at amortised cosl. using the effective interest rate method.
Trade creditors are obligations to pay lor goods or services that have been acquired in the ordinary course of
operations from suppliers. Amounts payable 8re dassified as current liabilities if payment is due wlhin one
year or le$5. If not. they are presented a5 non-current liabilities. Trade creditor5 are recogni$ed inth'ally 81
transactKJn price and subsequentty measure(1 at amortised cost usin9 the effectsve interest method.
D•rncognitlon of financlal liabiliti•s
Financial liabilities are derecogni5ed whtrn thtr Charty's ¢ontr8dual oblig81ion$ expire or a￿ discharged or
¢8ncelled.
1.12 Employe• b•n•fit8
The cost of any unused holiday trnlrflemenl is recooni8ed in thtr period in vthi¢h the employee's se￿￿8 arts
received.
Termination beneffts are recognlsed immediately as an expense when the charity Is demonstrably cornm￿ted
to temiinate the employment of an employee or to provide terniinalion beneffts.
1.13 Retlrem•nt benefits
Payments to defined contribulK)n retirement benefft schemes ara charged as an expense as they fall due.
crttlcal accoUn￿n9 estlmates and judgements
In the application of the ¢harity'5 accovnting poliryes. Ihe Trustees are required lo make judgement5.
estimate5 and assumptions aboul the carrying amounl ol a$5eis and liabilrties that are not readity apparent
from other sour¢es. Thè Èstimates and associaièd assump￿.0￿$ are basèd on hi$torieal experion¢g and other
factors that are considered to bè relevant. Actual resums may differ from these estimates.
The estimates and undertying assumptions a￿ reviewed on an ongoing basis. Revisions to accounting
estimates are recognised in the period in which the eslimale is revised where Ihe revision affects only that
period. or in the period ol the revision and ftjture peiiod5 where the revision affects bolh current and future
peri¢xls.
Kèy 8oure•# of •8tlmatlon uneèrtaonty
Falr value of Glfts In Klnd
The trustees have exercised judge￿nI in recoynising 8nd valuing grfts in kind. including donated goods 8nd
services. Recognition is made when entrtlement ts established, receipt is probable, and value can be ￿I1abty
measured.
Fair value is based on estimaled markel pri￿$ or equr¥alenl services rates at the dale of donation.
-22_

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Ineom• from donatlons and legael•s
Unrestrlcted Restrlcted
funds
lunds
2025
2025
Total Unrestrlcted Restrlcted
funds
funds
2024
2024
Total
202S
2024
Donations and gffts
Legacies
Grants receivable for core
8Ctivrties
17,607
626.267
1.000
581.248
12.848
11.264
592.512
12,848
1,0
1B.000
18.000
19,607
629,267
594.096
29.264
623,360
Income from other tradlng acVvltle¥
Unrnstrl¢t•d Unmtrl¢tgd
funds
funds
2025
2024
S81&s ol merchandise
2,354
2,943
Income trom Investment¥
Unmirf¢t•d Unrostrl¢t¢d
funds
funds
2025
2024
Interest re¢eivable
3,713
7,670
-23-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Exp•ndltur• on ralslng funds
Unrestrlcted Restricted
funds
funds
2025
202S
Total Unrestrlcted Restrlcted
funds
funds
2024
2024
Total
202S
2024
Fundraising and publicity
Fundraising costs
Stsff co$1$
Depreciation and
imp8irment
Support and govemance
costs
125,054
175,410
125,054
175.410
117.927
159.204
117,927
196,905
37,701
5.147
5.147
28,434
4,076
32,510
29.805
3,615
33,420
334.045
4.076
338.121
307.600
41.316
348.916
Tradlng costs
Other tradin9 activitie$
5,704
5.704
1S.157
15,157
Total costs
339,749
4.076
343.825
322.757
41.316
364,073
Exp•ndltur• on charftsbl• actlvltl••
Ralslng Supportlng
Medlcal
Patlent
awarene
ruearch educatlon 8UPPOrtllnfo
natlon
2025
Total
202S
2025
202S
2025
Dlrect costs
Staff costs
Depreciation and impainnent
Other costs
144,601
8.855
104,553
18.461
500
13.348
20.314
518
14.686
33,017
647
23,873
216,393
10.520
156,460
258.009
32,309
35.518
57,537
383,373
Share of support and governance cosls Isee note 9)
Support
19,651
Governance
6.537
2,509
835
2.760
918
4,487
1.493
29,407
9.783
284.197
35.653
39.196
63.517
422.563
Analysis by fund
Unrestricted funds
Restricted funds
261.767
22,430
21.892
13,761
26.530
12,666
41.375
22,142
351.564
70,999
284,197
35,653
39.196
63.517
422,563
-24_

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Expenditure on charitable activities
(Continuedl
Prèvlous yèar=
Ralslng Supportlng
M•dleal
Patl•nt
aVArèn•ss
rèsearch èducatlon supportllnfo
miatlon
2024
Total
2024
2024
2024
2024
Dlrèct costs
Stsff costs
Dep￿CiatIon and impaimient
Other costs
167.421
5.592
124.494
18.133
45
12.386
36.700
93
29.387
32.435
81
22,154
254.689
5,811
188,421
297,507
66,180
54,670
448,921
Shar• of support and gov•mane• eosts188• notè 91
Support
21.264
Governance
7,282
2.303
787
4.661
1.592
4.121
1,407
32.349
11,048
326,033
33,654
72.433
80,198
492,318
Analy81s by fvnd
Unrestricted funds
Restricted ftjnds
229,859
96,174
13.818
19,836
44.678
27.555
29,373
30,825
317,928
174,390
326,033
33,654
72,433
60,198
492,318
Tru•te
Non& ol the Twslees lor any persons ￿nn¢¢I&<I vnlh Ih¥ml r￿1¥&4 any ￿muneration durin9 the year and
none of them wgre fgimburs$d trav¢lling *x￿n$￿$(2o24- ÉNill.
-25-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
Support eosts alloeat•d to aetlvltl•s
Support Governance
eosts
costs
Support Governance
costs
costs
2025
2024
Rent
Office costs
Telephone costs
Computer costs
Insurance
Staff welfare
Training.
recruitment and
internship costs
Book-keeping and
accountancy
Bank charges
Audit fees
L89al and
professional
14,941
1.052
1,480
17.679
2,768
1,809
14.941
1.052
1.480
17.679
2.768
1.809
18,970
3.724
2,857
18.692
3,327
1.909
18,970
3.724
2,857
18.692
3,327
1,909
10.550
10.550
4.501
4.501
3,354
170
3.354
170
14.928
3,082
199
3,082
199
14,500
14.928
14.500
2,￿9
2.969
5,056
5,058
53,803
17.897
71.700
57.261
19.556
78,817
Analysed befv4een
Fundraising
Charitable activities
24.3
29,407
8.114
9,783
32.510
39.190
24.912
32,349
8.508
11,048
33.420
43,397
53,803
17,897
71.700
57.261
19.558
78,817
Governance costs include paymenls of £9,20012024 - £8,7501 plus VAT for audit fees and £3,04512024'. £2,900)
plus VAT for account5 preparalion fees.
10 Employèès
The average monthty number of employees during the yearwas=
2025
Number
2024
Number
13
-26-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
10 Employees
(Continuedl
Employmènt Costs
2025
2024
W8ges 8nd $818ries
Soaal security costs
Olhei pension costs
345.797
36,440
9,566
406,678
34,851
10,065
391,803
451,594
There were no &mploy&es whose annual remuneralK)n was MO￿ than £60.IXIO.
Ramunèratlon ol kay manag•m•nt pèrnonn•l
The remunerakn'on ol key management pef8onnel is as follows.
2025
2024
Aggregate ¢ompen$allon
61,684
52,429
The key management per$onn¥l of the Chanty 1$ ¢on$idef*d lo be ¢h& CEO. Th& In¢r*as* In KMP
remuneration 1$ due lo 8 ¢ross-ov&r of CEO'S durin9 the yè8(.
11 Taxatlon
The company is a registered charity and is. therefore. exempt from taxation on its charitable acts'vities.
12 Intanglble flxed a¥sets
Solts•*r•
Wèbilt•
D•v•k+pment
Coit•
Total
¢￿t
Al 1 J8nu8ry 2025
Additions- internalty developed
12.140
35.000
35.000
47,140
35,000
At 31 December 2025
12.140
70.000
82.140
Amort18ation and irnpairment
At 1 January 2025
Amortisation tharged for the yèar
1.128
4,006
1.128
6,509
2,503
At 31 December 2025
5,134
2,503
7,637
Carrylng amount
At 31 December 2025
67,497
74,503
At 31 December 2024
11,012
35,000
46,012
-27_

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
13 Tanglblè (lx￿ ass•ts
Flxtures.
fftUng$ &
Computers
Motor
vehl¢les
Totsl
C￿t
At 1 January 2025
18,032
6,758
20.000
42,790
At 31 December 2025
16.032
6.758
20.000
42.790
Dgpreclatlon and Impolnnont
At 1 January 2025
Dèpreciation charged in the y&ar
3,779
4,158
6,758
5.000
5,000
15,537
9,158
At 31 Do¢ember 2025
7,937
6,758
10,000
24,695
Carrylng amount
Al 31 December 2025
8,095
10,000
18,095
Al 31 December 2024
12,253
15,000
27,253
14 Sto¢k8
2025
2024
Flnl$hed goods and good$ lor rèsalg
9.378
4,565
10 D•btor•
2025
2024
Amounts lalllng du• wlthln on• yèar:
Prepayments and accrued income
84,869
54,37S
16 Cr•dltor8'. amounts falllng du• wothon on• yèar
202S
2024
Other taxation and social seujrity
Trade creditors
Other credrtors
Accruals and deferred income
11,011
8,954
156
36,927
12,171
36,322
19.265
26,106
57,048
93,864
-28-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
17 R•tlr•m•nt ￿n&fit seh•m•s
2025
2024
Defined contrlbutlon scheme8
Charge to the Staternent of Finanaal ACtiv￿e$ in respect of defined
contribution schemes
9.586
10.065
The charity operates a defined cx)ntribution pension scheme for all qualifying employees. The assets of the
scheme 8re held separatety from those ofthe charity in an independenuy 8dministered fund.
18 R•strfet•d lund$
The restricted funds ol the charity comprise the unexpended balances of donations and grants held on trust
subject to specAfic conditions by donors as to how they may be used.
At 1 January
2025
Incomlng
Source¥
Resourceo
?xpended
Trnn8fero
At31
Dec?mber
2025
Pat & Paul
Powapp
Recipe Book
PC Aware Campaign
Patiènt Infomalion Booklets
NIPanC
Research
Pancreatic Cancer Scotland
22,007
17.200
6,432
17.607
139.6141
17,200
4,427
500
{2.0051
{7.0001
5.845
22,000
24.456
5.845
20,000
12,0001
124.4561
103.440
19.607
175.0751
47,972
-29-

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
18 Restricted funds
(Continuedl
Prèvlous yèar=
At 1 January
2024
Ineomlng
rnsoure•s
R•soure•s
•x￿nd•d
Transfèrs
At31
Deeember
2024
Pat & Paul
Powapp
Recipe Book
PC Aware Campaign
HCP Education
Patient Information Booklets
NIPanC
Translation of resource
Research
Pancreatic Cancer Scotland
PC Aware North East England
A¢tion on th¢ Ground Glasgow
Project
Community volunteers
21.189
17,200
10,645
11.264
110.446
22.007
17,200
6,432
500
{4.213)
15.0001
{4.3201
{6.2731
5.500
3,500
8.000
820
5.273
5.000
5,845
5,845
493
22,500
175.197
20,000
1493
13,5001
1150.7411
120.0001
22,000
24,456
9,780
{9,7601
19601
283,789
29.264
1215.7C61
6,093
103,440
Reslricled ftjnds relaie 10 9rant$ received for Ihe $petyfi¢ purposes a8 Set out above. Any 8mounl unspent 18
carried lorwar¢J lo b¥ spent in ¢he next finon¢i81 year.
19 Analy•l8 of nèt a88•t8 b•t*wn fund•
Unmtrf¢ted
funds
2025
R*strl¢t¢d
funds
2025
Totgl
2025
At 31 Dec•mb•r 2025:
Intangible fixed asse15
Tangible assets
urrenl 8ssets1lliabilttiesl
74.503
18,09S
98.337
74,503
18,095
146,309
47.972
190,935
47,972
238,907

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
19 Analysis of net assets between funds
(Continuedl
Unr•strlet•d
fund8
2024
Rèstrfctèd
funds
2024
Total
2024
At 31 December 2024:
Intangible fixed assets
Tangible assets
Curr8nt assetsllliabilrti¢sl
46.012
27.253
193.256
46,012
27.253
296,696
103,440
286.521
103,440
369,961
20 Flnanclal commltm•nts, guarants•8 and contlngent Ilabllltl
To d8te, the charity h85 received £49.165 12024.. £48,235) in donalions from 80lirytors relating to old monies
held in dienl 8ccounl$ 1£18.979 < 5 years and £30.187 > S years) which they have ng1 been able lo rtrlurn.
There is a possibility that in the lutufe the dienls in question could still retum for these monies and, as such,
the charrty has agreed to refund part of the ¢Jonabon il Ihis occurs. No provision has been made In these
finanual statements for any possible refund as Ihe likelihood is remote and cannot be quantified, particularly
given the age of the undertying balances.
The Charity has committed lo sponsor a nursing ptsst vrithin NHS Greater Glasgow & Ctydtt IGGCI for a
further thre& year period, following the original thre& year commitment which $lart&d in January 2023. Th&
lot81 r$m8ining commilm¥nt a$ at O¥¢embef 2025 is É137,11212024". È46.8741.
During the year, the charity also r￿mmItted to paying for chanty insurance and for PR & Media Outreach and
monitoring seNices. The remaining wmmitmenis oulslanding al the year end are £782 and £2.325
respectively.
21 Related party tron¥•cllon•
There were no disdosable related party transactions during the year12024- none).
22 Cash absorbed by operntlons
2025
2024
Deficit for the year
1131,0541
1222,4181
Adlustrnents for..
Investment income recognised in statement of finanual activitse$
Depreciation and impaimient of langible fixed assets
13,7131
15.667
17,6701
8.475
Movement5 in working capital=
Ilncreasel in stocks
Ilncreaselldecrease in debtors
IDecreasellincrease in Creditors
14.8131
130,4941
136.8161
18901
24,823
57.654
Cash absorbed by operations
{191.2231
1142.0261
31

PANCREATIC CANCER ACTION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEAIBER 2025
23 Analysls ol Changès In nèt fvnds
The charity had no material debt durin9 the yeai.
-32_